Research programme: HIV infections - Cerep/Tibotec

Drug Profile

Research programme: HIV infections - Cerep/Tibotec

Alternative Names: HIV infections research programme - Cerep/Tibotec

Latest Information Update: 21 Feb 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cerep; Tibotec BVBA
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 21 Feb 2003 Discontinued - Preclinical for HIV infections treatment in Belgium (unspecified route)
  • 15 May 2002 Tibotec-Virco Group has been acquired by Johnson & Johnson
  • 09 Apr 2001 Tibotec has merged with Virco to form Tibotec-Virco Group
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top